Literature DB >> 25486347

Multi-target angiokinase inhibitors to fight resistance.

Oriol Casanovas1, Ramon Salazar, Josep Tabernero.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25486347      PMCID： PMC4613648          DOI： 10.4161/15384101.2014.954216

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.

Authors:  Elizabeth Allen; Ian B Walters; Douglas Hanahan
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

Review 2.  New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.

Authors:  Brian I Rini
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.

Authors:  Josep Tabernero; Rocio Garcia-Carbonero; James Cassidy; Alberto Sobrero; Eric Van Cutsem; Claus-Henning Köhne; Sabine Tejpar; Oleg Gladkov; Irina Davidenko; Ramon Salazar; Liubov Vladimirova; Sergey Cheporov; Olga Burdaeva; Fernando Rivera; Leslie Samuel; Irina Bulavina; Vanessa Potter; Yu-Lin Chang; Nathalie A Lokker; Peter J O'Dwyer
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

Review 4.  Resistance to targeted therapy in renal-cell carcinoma.

Authors:  Brian I Rini; Michael B Atkins
Journal:  Lancet Oncol       Date:  2009-10       Impact factor: 41.316

5.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

6.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Authors:  Frank Hilberg; Gerald J Roth; Martin Krssak; Susanna Kautschitsch; Wolfgang Sommergruber; Ulrike Tontsch-Grunt; Pilar Garin-Chesa; Gerd Bader; Andreas Zoephel; Jens Quant; Armin Heckel; Wolfgang J Rettig
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

7.  Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.

Authors:  Paul Mésange; Virginie Poindessous; Michèle Sabbah; Alexandre E Escargueil; Aimery de Gramont; Annette K Larsen
Journal:  Oncotarget       Date:  2014-07-15
  7 in total
  1 in total

1.  In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates.

Authors:  Peichen Pan; Huiyong Sun; Hui Liu; Dan Li; Wenfang Zhou; Xiaotian Kong; Youyong Li; Huidong Yu; Tingjun Hou
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.